Viking Therapeutics Advances Weight Loss Drug With Four Phase 3 Trials Underway
Biotech firm Viking Therapeutics is advancing its experimental obesity treatment VK2735 through four Phase 3 trials, aiming to tap into a high-demand market dominated by blockbusters like Eli Lilly's Zepbound.
🧠AI AnalysisPhoto: Motley Fool
Key points
- Viking Therapeutics has four Phase 3 trials underway for its VK2735 obesity drug.
- The trials test both subcutaneous and oral formulations, with results expected in 2027 and 2028.
- The company raised $547.8 million following encouraging mid-stage trial results.
- Key risks include managing side-effect tolerability and competing against rival blockbusters.
Biotechnology company Viking Therapeutics is currently advancing its flagship experimental weight-loss drug, VK2735, through four active Phase 3 trials. The ongoing studies evaluate both subcutaneous and oral formulations of the treatment for obesity and obesity combined with type 2 diabetes, with clinical results anticipated between 2027 and 2028.
Management's clinical strategy centers on offering flexible dosing options. This includes a potential dual formulation approach where patients could start with subcutaneous injections for rapid initial weight reduction and transition to a more convenient oral form for maintenance. The company recently raised a net $547.8 million through a stock and convertible senior notes offering following positive mid-stage data.
While early data from a small maintenance study showed promising weight-loss figures—reaching 21.7% in an exploratory cohort—analysts note significant hurdles remain. Previous tests of the oral formulation showed a 20% discontinuation rate due to adverse events, meaning future trials must prove both high efficacy and better patient tolerability to compete against established market giants like Eli Lilly and Novo Nordisk.
What to watch next: Investors should monitor the upcoming results from the second part of the ongoing maintenance study, which evaluates the transition from subcutaneous to oral dosing.
Source Motley Fool — fool.com/investing/2026/11/18/have-1000-this-beaten-down-biotech-ha… ↗
Read next
🧠AI AnalysisBitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce
Bitcoin remains constrained by a broader bearish pattern on short-term charts as dynamic trendline resistance caps recovery attempts. Although price recently rebounded fr…
🧠AI AnalysisMapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises
A breakdown of a $500 allocation into Infleqtion and Xanadu reveals the high-risk, high-reward nature of early-stage quantum computing investments.
🧠AI AnalysisBitcoin Eyes Resistance Near $61,800 Following Support Bounce
Bitcoin displays bullish momentum after rebounding from a key support zone, with potential movement toward the 61,800 resistance level.
🧠AI AnalysisAnalyst Suggests Taking Profits on Global X MSCI Colombia ETF
Market analysts recommend locking in gains on Colombian equities amid current macroeconomic conditions.
🧠AI AnalysisAnthropic IPO Momentum Fades as Stock Slips Below Opening Levels
Anthropic shares declined following a strong market debut, prompting market watchers to evaluate potential short-term downside risks.
📈MarketsBitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound
Bitcoin is hovering near a vital monthly support level, with technical analysts warning that a close below this threshold could risk a drop toward the $32,000 region.